Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.

James Chih-Hsin Yang,Geoffrey Liu,Shun Lu,Jianxing He,Mauricio Burotto,Myung-Ju Ahn,Dong-Wan Kim,XiaoQing Liu,Yanqiu Zhao,Sylvie Vincent,Jiani Yin, Xin Ma,Huamao M Lin,Sanjay Popat

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2023）

引用 0|浏览46

暂无评分

摘要

Brigatinib was not superior to alectinib for PFS in crizotinib-pretreated ALK+ NSCLC. Safety was consistent with the well-established and unique profiles of each drug. The low proportion of patients with ctDNA-detectable ALK fusion may account for prolonged PFS with both drugs in ALTA-3.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要